Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium.
Eng JW, Kato Y, Adachi Y, Swaminathan B, Naiche LA, Vadakath R, Sakamoto Y, Nakazawa Y, Tachino S, Ito K, Abe T, Minoshima Y, Hoshino-Negishi K, Ogasawara H, Kawakatsu T, Nishimura M, Katayama M, Shimizu M, Tahara K, Sato T, Suzuki K, Agarwala K, Iwata M, Nomoto K, Ozawa Y, Imai T, Funahashi Y, Matsui J, Kitajewski J. Eng JW, et al. Among authors: imai t. Cancer Res Commun. 2024 Jul 1;4(7):1881-1893. doi: 10.1158/2767-9764.CRC-24-0081. Cancer Res Commun. 2024. PMID: 38984877 Free PMC article.
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs.
Tsukamoto S, Sugi NH, Nishibata K, Nakazawa Y, Ito D, Fukushima S, Nakagawa T, Ichikawa K, Kato Y, Kakiuchi D, Goto A, Itoh-Yagi M, Aota T, Inoue S, Yamane Y, Murai N, Azuma H, Nagao S, Sasai K, Akagi T, Imai T, Matsui J, Matsushima T. Tsukamoto S, et al. Among authors: imai t. Mol Cancer Ther. 2023 Jan 3;22(1):12-24. doi: 10.1158/1535-7163.MCT-21-0879. Mol Cancer Ther. 2023. PMID: 36279567
Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.
Tanaka Y, Hoshino-Negishi K, Kuboi Y, Tago F, Yasuda N, Imai T. Tanaka Y, et al. Among authors: imai t. Immunotargets Ther. 2020 Nov 4;9:241-253. doi: 10.2147/ITT.S277991. eCollection 2020. Immunotargets Ther. 2020. PMID: 33178636 Free PMC article. Review.
Role of Anti-Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis.
Hoshino-Negishi K, Ohkuro M, Nakatani T, Kuboi Y, Nishimura M, Ida Y, Kakuta J, Hamaguchi A, Kumai M, Kamisako T, Sugiyama F, Ikeda W, Ishii N, Yasuda N, Imai T. Hoshino-Negishi K, et al. Among authors: imai t. Arthritis Rheumatol. 2019 Feb;71(2):222-231. doi: 10.1002/art.40688. Arthritis Rheumatol. 2019. PMID: 30079992
[Fractalkine and inflammatory diseases].
Imai T, Nishimura M, Nanki T, Umehara H. Imai T, et al. Nihon Rinsho Meneki Gakkai Kaishi. 2005 Jun;28(3):131-9. doi: 10.2177/jsci.28.131. Nihon Rinsho Meneki Gakkai Kaishi. 2005. PMID: 15997176 Free article. Review. Japanese.
Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis.
Kuboi Y, Suzuki Y, Motoi S, Matsui C, Toritsuka N, Nakatani T, Tahara K, Takahashi Y, Ida Y, Tomimatsu A, Soejima M, Imai T. Kuboi Y, et al. Among authors: imai t. Mol Ther Nucleic Acids. 2023 Jan 13;31:339-351. doi: 10.1016/j.omtn.2023.01.005. eCollection 2023 Mar 14. Mol Ther Nucleic Acids. 2023. PMID: 36789273 Free PMC article.
3,337 results